Compare TAL Education Group American Depositary Shares (TAL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAL Education Group American Depositary Shares vs Tango Therapeutics Inc. — how do they compare? TAL Education Group American Depositary Shares trades at $12.44 (market cap $6.94B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: TAL Education Group American Depositary Shares is the larger of the two by market cap, and TAL Education Group American Depositary Shares is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TAL Education Group American Depositary Shares for 3 Days and Tango Therapeutics Inc. for 0 Days on average.
| TAL | TNGX | |
|---|---|---|
Market Cap | $6.94B | $3.74B |
Volume | 4,522,975 | 3,438,781 |
Sector | Consumer Staples | Health |
52-Week High | $12.91 | $32.90 |
52-Week Low | $8.95 | $7.50 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $4.47B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAL Education Group trades at $12.64, down 0.63% with strong bullish technical signals from moving averages. The company demonstrates impressive fundamental strength with 28.43% net income margin and 23.72% ROE, supported by three consecutive earnings beats. Revenue growth accelerated from $2.25B in 2025 to $3.2B in 2026, while profitability surged from $85M to $907M net income. Analyst consensus shows 42.86% buy ratings with price targets suggesting 27.63% upside potential.
TAL presents a compelling investment case with strong earnings momentum and attractive valuation at 7.92 P/E. However, investors face risks from China's regulatory environment and the company's negative cash flow position of -$465.75M in 2025. The technical setup supports near-term upside with key resistance at $13 and support at $12, while institutional sentiment remains positive despite cash flow concerns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAL Education Group American Depositary Shares
TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
